Immunogenicity and Safety of Respiratory Syncytial Virus Vaccine in Lung Transplant Recipients
Analysis of Vaccine-induced Immune Responses and Optimization of Protective Immunity Against Respiratory Syncytial Virus in Lung Transplant Recipients
The purpose of this study is to compare the immunogenicity and safety of respiratory syncytial virus (RSV) vaccination between lung transplant recipients and immunocompetent adults and to provide evidence to guide RSV vaccination in lung transplant recipients.
研究概览
详细说明
- Lung transplant recipients and immunocompetent adults who are willing to receive a respiratory syncytial virus (RSV) vaccine will be recruited at the study hospital.
- Participants will receive a single intramuscular dose of the RSV vaccine (RSVPreF3, Arexvy®)
- Participants will be contacted by telephone on Day 7 and at the Day 30 follow-up visit after vaccination to assess adverse events.
- Immunogenicity will be evaluated before vaccination and at 1 month and 12 months after vaccination, and safety will be monitored throughout the study period.
- Changes in immune responses from pre-vaccination levels will be compared between lung transplant recipients and immunocompetent adults.
研究类型
注册 (估计的)
阶段
- 第四阶段
联系人和位置
学习联系方式
- 姓名:Chan Mi Lee, M.D., PhD.
- 电话号码:82-2-2072-1473
- 邮箱:heaven229@naver.com
研究联系人备份
- 姓名:Young Hoon Hwang, M.D.
- 电话号码:82-2-2072-2228
- 邮箱:hyh0307@gmail.com
学习地点
-
-
Jongno-Gu
-
Seoul、Jongno-Gu、韩国、03080
- 招聘中
- Seoul National University Hospital
-
接触:
- Nam Joong Kim, M.D., PhD.
- 电话号码:82-2-2072-0835
- 邮箱:njkmd@snu.ac.kr
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria (for lung transplant recipient) :
- Adults aged 19 years or older who voluntarily provide written informed consent to participate in the study
- Recipients of a lung transplant who are receiving immunosuppressive therapy to prevent allograft rejection.
Inclusion Criteria (for control) :
- Adults aged 60 years or older who voluntarily provide written informed consent to participate in the study.
- Individuals who do not have medical conditions associated with immunocompromise (e.g., malignancy, bone marrow transplantation, solid organ transplantation, HIV infection, or dialysis) and have not received ongoing chemotherapy, radiation therapy, immunosuppressive therapy, or immunomodulatory therapy within 6 months before vaccination.
Exclusion Criteria:
Participants will be excluded if they meet any of the following criteria
- Previous receipt of any RSV vaccine.
- RSV infection diagnosed within the past 12 months.
- History of a severe allergic reaction to any component of the RSV vaccine.
- Moderate or severe acute illness at the time of screening.
- Pregnancy, planned pregnancy, or breastfeeding.
- Any underlying medical condition for which intramuscular injection is contraindicated.
- Any other condition that, in the investigator's judgment, may make the participant unsuitable for evaluation of immune responses.
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Lung transplant recipient
Lung transplant recipients aged ≥19 years receiving immunosuppressive therapy (n=60) |
One dose of RSVPreF3 (Arexvy®) vaccine |
|
有源比较器:Control
Immunocompetent adults aged ≥60 years (n=20) |
One dose of RSVPreF3 (Arexvy®) vaccine |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Humoral immune response (neutralizing antibody)
大体时间:1 month after vaccination
|
Geometric mean fold rise (GMFR) in RSV-A neutralizing antibody titers from pre-vaccination to 1 month after vaccination, compared between lung transplant recipients and immunocompetent adults. |
1 month after vaccination
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Humoral immune response (neutralizing antibody)
大体时间:Prevaccination, 1 month and 12 months after vaccination
|
Geometric mean titers (GMTs) in RSV-A neutralizing antibody titers |
Prevaccination, 1 month and 12 months after vaccination
|
|
Humoral immune response (neutralizing antibody)
大体时间:Prevaccination, 1 month and 12 months after vaccination
|
Geometric mean titers (GMTs) in RSV-B neutralizing antibody titers |
Prevaccination, 1 month and 12 months after vaccination
|
|
Humoral immune response (neutralizing antibody)
大体时间:1 month, 12 months after vaccination
|
Geometric mean fold rises (GMFRs) in RSV-A neutralizing antibody titers from pre-vaccination levels. |
1 month, 12 months after vaccination
|
|
Humoral immune response (neutralizing antibody)
大体时间:1 month, 12 months after vaccination
|
Geometric mean fold rises (GMFRs) in RSV-B neutralizing antibody titers from pre-vaccination levels. |
1 month, 12 months after vaccination
|
|
Humoral immune response (RSV specific antibody)
大体时间:Prevaccination, 1 month and 12 months after vaccination
|
Geometric mean concentrations (GMCs) in RSVPreF3-specific IgG |
Prevaccination, 1 month and 12 months after vaccination
|
|
Humoral immune response (RSV specific antibody)
大体时间:Prevaccination, 1 month and 12 months after vaccination
|
Geometric mean concentrations (GMCs) in pan-RSV-specific IgG |
Prevaccination, 1 month and 12 months after vaccination
|
|
Humoral immune response (RSV specific antibody)
大体时间:1 month, 12 months after vaccination
|
Geometric mean fold rises (GMFRs) in RSVPreF3-specific IgG from pre-vaccination levels. |
1 month, 12 months after vaccination
|
|
Humoral immune response (RSV specific antibody)
大体时间:1 month, 12 months after vaccination
|
Geometric mean fold rises (GMFRs) in pan-RSV-specific IgG from pre-vaccination levels. |
1 month, 12 months after vaccination
|
|
Humoral immune response (serologic response rate)
大体时间:1 month, 12 months after vaccination
|
Proportion of participants with a ≥4-fold increase in antibody levels from pre-vaccination levels |
1 month, 12 months after vaccination
|
|
Cell mediated immunity
大体时间:1 month, 12 months after vaccination
|
Frequency of RSV F-specific CD4+ and CD8+ T cells following stimulation with RSV F peptide pools, measured by flow cytometry. |
1 month, 12 months after vaccination
|
|
Safety (solicited adverse events)
大体时间:7 days, 30 days after vaccination
|
Proportion of participants experiencing solicited local and systemic adverse events following vaccination. |
7 days, 30 days after vaccination
|
|
Safety (unsolicited adverse events, serious adverse events)
大体时间:Up to 12 months after vaccination
|
Proportion of participants experiencing unsolicited adverse events or serious adverse events following vaccination. |
Up to 12 months after vaccination
|
合作者和调查者
调查人员
- 首席研究员:Nam Joong Kim, M.D., PhD.、Seoul National University Hospital
出版物和有用的链接
一般刊物
- Walsh EE, Perez Marc G, Zareba AM, Falsey AR, Jiang Q, Patton M, Polack FP, Llapur C, Doreski PA, Ilangovan K, Ramet M, Fukushima Y, Hussen N, Bont LJ, Cardona J, DeHaan E, Castillo Villa G, Ingilizova M, Eiras D, Mikati T, Shah RN, Schneider K, Cooper D, Koury K, Lino MM, Anderson AS, Jansen KU, Swanson KA, Gurtman A, Gruber WC, Schmoele-Thoma B; RENOIR Clinical Trial Group. Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults. N Engl J Med. 2023 Apr 20;388(16):1465-1477. doi: 10.1056/NEJMoa2213836. Epub 2023 Apr 5.
- Tan CS, Anjan S, Ariza-Heredia EJ, Magana F, Minniear TD, Kaur D, Falck-Ytter Y, Baden L. IDSA 2025 Guidelines on the Use of Vaccines for the Prevention of Seasonal RSV Infections in Immunocompromised Patients. Clin Infect Dis. 2026 Aug 24;82(Suppl 3):i123-i128. doi: 10.1093/cid/ciag117.
- Mayer EF, Falsey AR, Wolfe CR, Herc E, Burns F, Kabbani D, Kumar D, Mannan A, She F, Lan L, McGrath S, Kapoor A, Priddy F. Respiratory Syncytial Virus Vaccination in Solid Organ Transplant Recipients: Interim Findings From a Phase 3 Trial of mRNA-1345. Clin Infect Dis. 2026 May 20;82(5):e1112-e1121. doi: 10.1093/cid/ciag108.
- Levy L, Yahav D, Benzimra M, Bezalel Y, Hoffman T, Shirin N, Sinai T, Jurkowicz M, Deri O, Matalon N, Saute M, Lustig Y, Nachum E, Peled M, Nemet I, Mandelboim M. Neutralizing Antibody Response to the AreXvy Respiratory Syncytial Virus Vaccine in Lung Transplant Recipients: Assessment Against Reference and Seasonal Strains. Vaccines (Basel). 2025 Apr 11;13(4):398. doi: 10.3390/vaccines13040398.
- Ferguson M, Schwarz TF, Nunez SA, Rodriguez-Garcia J, Mital M, Zala C, Schmitt B, Toursarkissian N, Mazarro DO, Grosskopf J, Voors-Pette C, Mehta H, Hailemariam HA, de Heusch M, Salaun B, Damaso S, David MP, Descamps D, Hill J, Vandermeulen C, Hulstrom V; RSV OA=ADJ-018 Study Group. Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50-59 Years Compared to >/=60 Years of Age. Clin Infect Dis. 2024 Oct 15;79(4):1074-1084. doi: 10.1093/cid/ciae364.
- Britton A, Roper LE, Kotton CN, Hutton DW, Fleming-Dutra KE, Godfrey M, Ortega-Sanchez IR, Broder KR, Talbot HK, Long SS, Havers FP, Melgar M. Use of Respiratory Syncytial Virus Vaccines in Adults Aged >/=60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2024. MMWR Morb Mortal Wkly Rep. 2024 Aug 15;73(32):696-702. doi: 10.15585/mmwr.mm7332e1.
- Melgar M, Britton A, Roper LE, Talbot HK, Long SS, Kotton CN, Havers FP. Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023 Jul 21;72(29):793-801. doi: 10.15585/mmwr.mm7229a4.
- Papi A, Ison MG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Campora L, Dezutter N, de Schrevel N, Fissette L, David MP, Van der Wielen M, Kostanyan L, Hulstrom V; AReSVi-006 Study Group. Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults. N Engl J Med. 2023 Feb 16;388(7):595-608. doi: 10.1056/NEJMoa2209604.
- Tseng HF, Sy LS, Ackerson B, Solano Z, Slezak J, Luo Y, Fischetti CA, Shinde V. Severe Morbidity and Short- and Mid- to Long-term Mortality in Older Adults Hospitalized with Respiratory Syncytial Virus Infection. J Infect Dis. 2020 Sep 14;222(8):1298-1310. doi: 10.1093/infdis/jiaa361.
- Na SH, Jo HJ, Park JJ, Seo Y, Lee J, Bae J, Lee M, Lee CM, Kang CK, Choe PG, Park WB, Kim NJ. Comparison of clinical characteristics and outcomes in hospitalized adult patients infected with respiratory syncytial virus and influenza virus. Infect Dis (Lond). 2025 Feb;57(2):159-166. doi: 10.1080/23744235.2024.2402914. Epub 2024 Sep 16.
- de Zwart A, Riezebos-Brilman A, Lunter G, Vonk J, Glanville AR, Gottlieb J, Permpalung N, Kerstjens H, Alffenaar JW, Verschuuren E. Respiratory Syncytial Virus, Human Metapneumovirus, and Parainfluenza Virus Infections in Lung Transplant Recipients: A Systematic Review of Outcomes and Treatment Strategies. Clin Infect Dis. 2022 Jul 6;74(12):2252-2260. doi: 10.1093/cid/ciab969.
- Havers FP, Whitaker M, Melgar M, Chatwani B, Chai SJ, Alden NB, Meek J, Openo KP, Ryan PA, Kim S, Lynfield R, Shaw YP, Barney G, Tesini BL, Sutton M, Talbot HK, Olsen KP, Patton ME; RSV-NET Surveillance Team. Characteristics and Outcomes Among Adults Aged >/=60 Years Hospitalized with Laboratory-Confirmed Respiratory Syncytial Virus - RSV-NET, 12 States, July 2022-June 2023. MMWR Morb Mortal Wkly Rep. 2023 Oct 6;72(40):1075-1082. doi: 10.15585/mmwr.mm7240a1.
- Tin Tin Htar M, Yerramalla MS, Moisi JC, Swerdlow DL. The burden of respiratory syncytial virus in adults: a systematic review and meta-analysis. Epidemiol Infect. 2020 Feb 13;148:e48. doi: 10.1017/S0950268820000400.
- Solidoro P, Curtoni A, Minuto S, Shbaklo N, De Rosa FG, Bondi A, Sidoti F, Patrucco F, Zanotto E, Corcione S, Boffini M, Marro M, Costa C, Rinaldo RF. Impact of RSV Infection in Transplant and Immunocompromised Population: Incidence and Co-Infections: Retrospective Analysis of a Single Centre. J Clin Med. 2025 Jul 7;14(13):4803. doi: 10.3390/jcm14134803.
- Mahan LD, Points A, Mohanka MR, Bollineni S, Joerns J, Kaza V, La Hoz RM, Gao A, Zhang S, Torres F, Banga A. Characteristics and outcomes among lung transplant patients with respiratory syncytial virus infection. Transpl Infect Dis. 2021 Aug;23(4):e13661. doi: 10.1111/tid.13661. Epub 2021 Jun 22.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他研究编号
- 2608-187-1775
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
We are not planning to share IPDs publically, but de-identified individual participant data for all outcome measures could be shared with other researchers under their request.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.